Revenue
2011
2012
2014
2015
2016
2017
2018
2019
2020
2020
2021
2022
2023
2024
2025
Yubo International Biotech Ltd (YBGJ)
Price$0.0108Cached quote
Net income
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
Total cash / debt
CashTotal debt
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 · Dec 31 | 2020 · Feb 29 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12,353 | $3,470 | $604,676 | $104,283 | $1.2M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | $0 | $0 |
| Gross profit | $8,165 | $2,648 | $419,185 | $52,652 | $820,647 | $1.2M | — | — | — | — | — | — | — | — | — | — |
| Gross margin | 66.10% | 76.31% | 69.32% | 50.49% | 65.95% | — | — | — | — | — | — | — | — | — | — | — |
| Operating expenses | $1.2M | $1.8M | $1.6M | $1.3M | $2.4M | $2.0M | — | — | — | — | — | — | — | — | — | — |
| Operating income | −$1.2M | −$1.8M | −$1.2M | −$1.2M | −$1.5M | −$711,798 | −$29,000 | −$48,000 | −$58,000 | −$149,000 | −$63,000 | −$58,000 | −$55,000 | −$60,000 | −$47,000 | −$80,000 |
| Operating margin | −9,614.64% | −51,006.31% | −197.58% | −1,155.72% | −123.99% | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −$1.0M | −$1.6M | −$1.0M | −$1.2M | −$1.5M | −$698,735 | — | — | — | — | — | — | — | — | — | — |
| EBITDA margin | −8,258.03% | −46,110.78% | −168.09% | −1,138.37% | −122.92% | — | — | — | — | — | — | — | — | — | — | — |
| Net income | −$1.1M | −$1.8M | −$1.2M | −$1.2M | −$1.5M | −$711,801 | −$134,000 | −$148,000 | −$144,000 | −$224,000 | −$130,000 | −$116,000 | −$106,000 | −$103,000 | −$84,000 | −$110,000 |
| Net profit margin | −8,736.73% | −51,171.41% | −197.64% | −1,155.50% | −123.95% | — | — | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$0.01 | -$0.02 | -$0.01 | -$0.01 | -$0.01 | $0.01 | -$0.11 | -$0.13 | -$0.12 | -$0.19 | -$0.11 | -$0.10 | -$0.09 | -$0.09 | -$0.07 | -$0.09 |
| Diluted EPSper diluted share | -$0.01 | -$0.02 | -$0.10 | -$0.01 | -$0.01 | $0.01 | -$0.11 | -$0.13 | -$0.12 | -$0.19 | -$0.11 | -$0.10 | -$0.09 | -$0.09 | -$0.07 | -$0.09 |
Owners
Reported shareholders
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jul 15, 2024Form 4 | Wang YangChief Executive Officer | SellClass A Common Stock · indirect | 2.00M | $0.12 | $240.0K | 17.21M |
| Jan 25, 2024Form 4 | CAO YULIN +1TenPercentOwner | SellClass A Common Stock | 380.2K | $0.30 | $114.1K | 19.93M |
| Jan 25, 2024Form 4 | CAO YULIN +1TenPercentOwner | SellClass A Common Stock | 2.06M | $0.30 | $617.3K | 20.31M |
| Jan 25, 2024Form 4 | CAO YULIN +1TenPercentOwner | SellClass A Common Stock | 426.7K | $0.30 | $128.0K | 22.37M |
| Jan 25, 2024Form 4 | CAO YULIN +1TenPercentOwner | SellClass A Common Stock | 86.9K | $0.30 | $26.1K | 22.79M |